Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Noel

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|January 11, 2019
Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?Tania Jain, Katie L Kunze, Banveet K Khetarpal, et al.
British Journal of Haematology|March 22, 2016
Monoclonal gammopathy-associated pure red cell aplasiaNeha Korde, Yong Zhang, Kelsey Loeliger, et al.
Haematologica|January 2, 2008
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusionIdoya Lahortiga, Cem Akin, Jan Cools, et al.
Blood|August 22, 2007
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingAmy D Klion, Jamie Robyn, Irina Maric, et al.
Leukemia & Lymphoma|July 7, 2018
Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantationTania Jain, Heidi E Kosiorek, Thomas E Grys, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2007
KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entitiesIrina Maric, Jamie Robyn, Dean D Metcalfe, et al.
Therapie|July 10, 2016
[Not Available]Pierre Noel Lirsac, Olivier Blin, Jérémy Magalon, et al.
Blood Neoplasia|January 23, 2026
Extended long-term follow-up and the survival of Stop Imatinib studyFrançois-Xavier Mahon, Stéphanie Dulucq, Delphine Réa, et al.
Therapie|March 10, 2015
Creating conditions for the success of the French industrial advanced therapy sectorPierre Noel Lirsac, Olivier Blin, Jérémy Magalon, et al.
Haematologica|April 22, 2011
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implicationsKatherine R Calvo, Donald C Vinh, Irina Maric, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|January 11, 2019
Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?Tania Jain, Katie L Kunze, Banveet K Khetarpal, et al.
British Journal of Haematology|March 22, 2016
Monoclonal gammopathy-associated pure red cell aplasiaNeha Korde, Yong Zhang, Kelsey Loeliger, et al.
Haematologica|January 2, 2008
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusionIdoya Lahortiga, Cem Akin, Jan Cools, et al.
Blood|August 22, 2007
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingAmy D Klion, Jamie Robyn, Irina Maric, et al.
Leukemia & Lymphoma|July 7, 2018
Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantationTania Jain, Heidi E Kosiorek, Thomas E Grys, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2007
KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entitiesIrina Maric, Jamie Robyn, Dean D Metcalfe, et al.
Therapie|July 10, 2016
[Not Available]Pierre Noel Lirsac, Olivier Blin, Jérémy Magalon, et al.
Blood Neoplasia|January 23, 2026
Extended long-term follow-up and the survival of Stop Imatinib studyFrançois-Xavier Mahon, Stéphanie Dulucq, Delphine Réa, et al.
Therapie|March 10, 2015
Creating conditions for the success of the French industrial advanced therapy sectorPierre Noel Lirsac, Olivier Blin, Jérémy Magalon, et al.
Haematologica|April 22, 2011
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implicationsKatherine R Calvo, Donald C Vinh, Irina Maric, et al.
Pageof 7